Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients With Lymphoid Malignancies (OPAL Study)

Next Previous
Trial Profile

An Open Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients With Lymphoid Malignancies (OPAL Study)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Hydrocortisone; Proton pump inhibitors
  • Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Registrational
  • Acronyms OPAL
  • Sponsors AVM Biotechnology

Most Recent Events

  • 04 Jun 2024 Results (cutoff date of Dec 13, 2023) assessing durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immuno-activating AVM0703 with few and mild drug-related adverse effects presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 11 Sep 2023 According to an AVM Biotechnology media release, phase 2 adaptive design/expansion cohorts for immunomodulatory AVM0703 in relapsed/refractory Non-Hodgkin Lymphoma/Leukemia patients, will be present at the Bio Investor Forum, held in San Francisco, CA October 17-18, 2023.
  • 09 Aug 2023 According to an AVM Biotechnology media release, companys application was scored by reviewers from venture capital, validating that the company is well-positioned to bring-in significant funds in 2023-2024 to support our enrolling Phase 2 adaptive-design expansion trial in no-option Non-Hodgkins Lymphoma/Leukemia patients and to broaden our clinical trial activity to solid tumor patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top